Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decline in Short Interest

Apollomics, Inc. (NASDAQ:APLMW) was the recipient of a significant decline in short interest during the month of January. As of January 15th, there was short interest totalling 700 shares, a decline of 99.0% from the December 31st total of 68,200 shares. Based on an average daily trading volume, of 82,000 shares, the days-to-cover ratio is presently 0.0 days.

Apollomics Trading Down 0.9 %

Apollomics stock traded down $0.00 during mid-day trading on Tuesday, hitting $0.01. The company’s stock had a trading volume of 1,400 shares, compared to its average volume of 18,525. Apollomics has a twelve month low of $0.01 and a twelve month high of $0.04. The stock’s fifty day moving average price is $0.01 and its two-hundred day moving average price is $0.01.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.